metallodrugs

Term used to define a pharmaceutical, having a activity center containing a metal. Platinum (cisplatin, carboplatin) and gold (Auranofin) compounds are well-known in cancer therapy whereas some other gold compounds (aurithiomalate, aurothioglucose) are important antiarthritic drugs. A wide range of Tc compounds (e.g. Tc-labelled antibodies, Tc-mercaptoacetyl glycine complex) are used for diagnostic imaging of renal, cardiac and cerebral functions and of various forms of cancer. Gadolinium (III) polyaminopolycarboxylic crown complexes are widely used as contrast agents in magnetic resonance imaging.



The term "metallodrugs" was found in the following pages:

European Medicines Agency recomments to pull linear Gadolinium-based MRI contrast agents from market | EVISA's News
Scientific publications with participation of EVISA | EVISA's News
Link database: Italy: Interdepartmental Research Center “Role of Metal Ions in Biomedical Sciences - BIOMÉTION”
Link database: NL: Groningen Research Institute of Pharmacy (GRIP)
Efficiency of some papillomavirus vaccines is reduced in the presence of thimerosal | EVISA's News
All about Pharmacy and Pharmaceutical Sciences | EVISA's News
FDA investigating risk of gadolinium contrast agent brain deposits | EVISA's News
What's new ? | EVISA's News
Non-chromatographic separation techniques for speciation analysis | EVISA's News
Gadolinium found in the brain of a patient two years after having received a Gd-based contrast agent for medical imaging | EVISA's News
Research fields related to elemental speciation
Tracing Gadolinium-based Contrast Agents from Wastewater, via Surface Water to Drinking Water | EVISA's News
Link database: USA: Ohio State University: Cowan Group
CDC's Vaccine Safety Research is Exposed as Flawed and Falsified in Peer-Reviewed Scientific Journal | EVISA's News
Chemical Speciation Modeling | EVISA's News
Directory of scientists: Katarzyna Pawlak
European Medicines Agency recommends to pull linear Gadolinium-based MRI contrast agents from market | EVISA's News
Books and Special Issues on Elemental Speciation (published since 2006) | EVISA's News
FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs | EVISA's News
Directory of scientists: Michael Sperling